Karyopharm Enters Chapter 11 with Ayrmid as Lead Bidder

Company Karyopharm Therapeutics; Ayrmid (Gamida Cell) Event Type Chapter 11 filing and proposed merger Modality XPO1 inhibitor (commercial small molecule) Asset Selinexor Target XPO1 Disease Area Relapsed or refractory multiple myeloma; myelofibrosis Summary Karyopharm filed voluntary Chapter 11 petitions on November 2 and signed a…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

AstraZeneca Licenses Dizal’s Zegfrovy for Up to $1.5B
Vaderis Raises $152 Million and Starts HEROIC
Tectora Launches With 55 Million Dollars
CSL Licenses Lixudebart in $355 Million Initial Deal